{"organizations": [], "uuid": "65934c1807295d54e9a3a7b8d08c1d47a682e019", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pharming-group-q4-revenues-from-pr/brief-pharming-group-q4-revenues-from-product-sales-of-eur-32-7-mln-up-26-pct-vs-q3-idUSFWN1QP02X", "country": "US", "domain_rank": 408, "title": "BRIEF-Pharming Group Q4 Revenues From Product Sales OF EUR 32.7 Mln, Up 26 Pct Vs. Q3", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.748, "site_type": "news", "published": "2018-03-07T14:19:00.000+02:00", "replies_count": 0, "uuid": "65934c1807295d54e9a3a7b8d08c1d47a682e019"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pharming-group-q4-revenues-from-pr/brief-pharming-group-q4-revenues-from-product-sales-of-eur-32-7-mln-up-26-pct-vs-q3-idUSFWN1QP02X", "ord_in_thread": 0, "title": "BRIEF-Pharming Group Q4 Revenues From Product Sales OF EUR 32.7 Mln, Up 26 Pct Vs. Q3", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "pharming", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - PHARMING GROUP NV:\n* DELIVERED REVENUE FOR FULL YEAR OF EUR 89.6 MILLION (US$101.2 MILLION) - AN INCREASE OF 464% ON 2016\n* Q4 REVENUES FROM PRODUCT SALES OF EUR 32.7M (US$39.2 MILLION) - UP 26% COMPARED TO Q3\n* FULL YEAR REVENUES FROM PRODUCT SALES WERE EUR 88.7 MILLION, UP 547% UP ON 2016,\n* EUR 21.4 MILLION OF NET CASH GENERATED IN Q4 ALONE * DURING 2018, WE EXPECT THAT COMPANY WILL AGAIN ACHIEVE A POSITIVE RESULT.\n* FULL YEAR NET CASH PROFITS, INCLUDING PAYMENTS OF INTEREST BUT BEFORE ONE-OFF REFINANCING COSTS AND NON-CASH ADJUSTMENTS, WERE EUR 12.9 MILLION\n* SEES FOR 2018 ACHIEVEMENT OF POSITIVE NET EARNINGS FOR AT LEAST ONE QUARTER DURING YEAR.\n* SEES FOR 2018 CONTINUED GROWTH IN REVENUES FROM SALES OF RUCONEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-07T14:19:00.000+02:00", "crawled": "2018-03-08T17:00:43.000+02:00", "highlightTitle": ""}